I think this is a normal part of the process. Large numbers of people participate in the trials for new treatments. People sometimes fall ill during trials for reasons that may or may not be connected to use of the experimental treatment. When they fall ill, they pause the trial to see if the treatment was the cause.
They paused the UK trial also, but established the treatment wasn't the cause. Turned out it was a coincidence. Then the trial continued. Hopefully, the same will be the case for J&J and Eli Lilly. Checking why people get ill (and pausing while doing so to protect the other participants) is part of the normal process. If they didn't, the trial lawyers would kill the drug companies.
Another example. Regeneron is in its early phase of testing. Turns out one of the participants in its trial (albeit on a compassionate waiver) seemed to be unhinged. Luckily, it turned out he already was. Another coincidence. And so he was able to go back to doing what he was doing before. Being president. And Regeneron continued its trial.
| 